Phase 1 Study of ONT-10 in Patients With Solid Tumors

Solid Tumors Clinical Trial

Official title:

Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01556789
• Other study ID #: ONT-10-001
• Status: Completed
• Phase: Phase 1
• Start date: March 2013
• Est. completion date: September 2015

Study information

• Verified date: September 2015
• Source: Seattle Genetics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open label, two part, Phase 1 dose escalation study to evaluate the safety and immunogenicity of repeat dose vaccination with ONT-10 in patients with previously treated Stage 3 or 4 solid tumors. Part 1 to evaluate escalating dose levels of ONT-10 administered subcutaneously every two weeks (Q2W) or weekly (QW) over 8 weeks. Part 2 evaluates the safety, immunogenicity, and potential anti-tumor activity of ONT-10 administered over 8 weeks at the Q2W and QW maximum tolerated does/recommended dose (MTD/RD) in cohorts of 15 patients each.

Description:

This open label, two part, Phase 1 dose escalation study will evaluate the safety and immunogenicity of repeat dose vaccination with ONT-10 in patients with previously treated Stage 3 or 4 solid tumors with histologies that have been associated with expression of the MUC1 antigen as described in the medical literature. Part 1 will evaluate escalating dose levels of ONT-10 administered subcutaneously Q2W over 8 weeks (for a total of 4 doses) or QW over 8 weeks (for a total of 8 doses) to identify a MTD and/or RD for each dosing schedule, for further evaluation in Part 2 of the study. Part 2 will evaluate the safety, immunogenicity, and potential anti-tumor activity of ONT-10 administered over 8 weeks at the Q2W and QW MTD/RD in cohorts of 15 patients each.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: September 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Be 18 to 70 years of age at time of consent

2. Life expectancy of at least 6 months, in the opinion of the investigator

3. A) Have histologically confirmed breast, non-small cell lung, ovarian, colorectal, gastric, prostate, pancreatic, or renal cell cancer, or other tumor type as approved by the study medical monitor (Part 1) B) Have histologically confirmed breast or ovarian carcinoma (Part 2)

4. Have evidence of persistent, recurrent, or progressive disease after at least one course of systemic therapy for locally advanced or metastatic disease, including chemotherapy, targeted therapy, or immunotherapy

5. Clinical stage 3 or 4 disease

6. ECOG 0 or 1

7. Adequate baseline hematological parameters as defined by white blood cell count (WBC) = 3.5 x 103/uL, lymphocyte count = 1.0 x 103/uL, platelet count = 100 x 103/uL, and hemoglobin = 9 g/dL

8. Have renal and hepatic function laboratory test results not to exceed 1.5 X upper limit of normal (ULN)

9. If female of child bearing potential, have a negative pregnancy test at screening

10. If fertile male or female of child-bearing potential, agree to consistently use a highly effective method of birth control (including birth control pills, barrier device, or intrauterine device) from the time of consent through 3 months following the last dose of study drug.

11. Be able and willing to sign informed consent document that has been approved by an institutional review board or independent ethics committee (IRB/IEC)

Exclusion Criteria:

1. Has medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures

2. Is pregnant, breastfeeding, or planning a pregnancy

3. Has received treatment with any systemic chemotherapy, radiation, or experimental agent within 4 weeks of study drug dosing

4. Has untreated or uncontrolled central nervous system (CNS) metastases, including patients who require glucocorticoid therapy for CNS metastases.

5. Has a known history of autoimmune disease, arteritis, or vasculitis, including, but not limited to: lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease (including ulcerative colitis and Crohn's disease), Grave's disease, Hashimoto's thyroiditis, Wegener's granulomatosis, temporal arteritis, and polyarteritis nodosa

6. Has a recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia; and/or other hereditary or congenital immunodeficiencies

7. Has any preexisting medical condition requiring chronic steroid or immunosuppressive therapy (corticosteroids for COPD or topical steroids are allowed)

8. Known to be positive for HIV, hepatitis B, or hepatitis C

9. Administration of any other vaccine = 4 weeks prior to study enrollment

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Biological:
• ONT-10
ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.

Locations

Country	Name	City	State
United States	University of Colorado Cancer Center	Aurora	Colorado
United States	Mary Crowley Cancer Research Center	Dallas	Texas
United States	Northwest Medical Specialties, PLLC	Tacoma	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Cascadian Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety	Assessment of adverse events and laboratory abnormalities	20 weeks
Secondary	Immunogenicity	Assessments to include evaluation of humoral and cellular immune response.	20 weeks